Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductionsGinkgo signs new and expanded deals with Novo Nordisk and achieves a major research milestone with Merck  BOSTON, Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September 30, 2024. The upda ...

Core Insights - Ginkgo Bioworks has completed the first milestone of its partnership with Merck, receiving a cash payment of $9 million [1][2][3] - The next phase of the partnership will focus on further improving the biologic manufacturing process [2][3] Company Overview - Ginkgo Bioworks is a leading platform for cell programming, offering end-to-end services across various markets, including pharmaceuticals and biosecurity [4] - The company emphasizes its capabilities in strain engineering, high-throughput screening, and process development, positioning itself as a valuable partner for pharmaceutical companies [3][4]

Presentation and Q&A session scheduled for post-market on Tuesday, November 12, 2024 BOSTON, Nov. 5, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2024, on Tuesday, November 12, 2024, beginning at 5:30 p.m. ET.The presentation details and webcast link will be ava ...

Ginkgo Bioworks Holdings, Inc. (DNA) ended the recent trading session at $7.63, demonstrating a -1.55% swing from the preceding day's closing price. This change lagged the S&P 500's 0.28% loss on the day. Elsewhere, the Dow lost 0.61%, while the tech-heavy Nasdaq lost 0.33%.The company's stock has dropped by 6.96% in the past month, falling short of the Medical sector's loss of 3.47% and the S&P 500's gain of 0.41%.Investors will be eagerly watching for the performance of Ginkgo Bioworks Holdings, Inc. in i ...

MENLO PARK, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced SPRQ, an improved sequencing chemistry for its Revio™ long-read sequencing system. The new chemistry will reduce Revio DNA input requirements by 4x to 500ng per sample, which enables more sample types such as saliva extracted with PacBio’s new Nanobind protocol and tumor samples to be sequenced with HiFi sequencing technology. It will also in ...

Dublin, Oct. 28, 2024 (GLOBE NEWSWIRE) -- The "DNA & RNA Banking Services Market Size, Share and Trends Analysis Report by Service, Specimen (Blood, Buccal Swabs & Hair Follicles, Others), Application, End-use 2024-2030" report has been added to ResearchAndMarkets.com's offering. The global DNA & RNA banking services market size is expected to reach USD 10.92 billion by 2030, registering a CAGR of 5.5% from 2024 to 2030. Biospecimens such as DNA and RNA are critical for biomarker discovery, thereby providin ...

NEW HAVEN, Conn., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Modifi Biosciences, Inc. (“Modifi Biosciences”), a leader in the development of direct DNA modification enabled cancer therapeutics, today announced that the company has been acquired by Merck, known as MSD outside of the United States and Canada. “In founding Modifi Biosciences, we sought to radically change the oncology treatment paradigm for cancer patients with glioblastoma and other tumors,” said Ranjit S. Bindra, MD, PhD, Modifi Biosciences Co-founde ...

Market Overview - The global pet DNA testing market is projected to reach USD 676.64 million by 2030, growing at a CAGR of 9.45% from 2024 to 2030 [1][12] - The U.S. pet industry expenditure increased from USD 103.6 billion in 2020 to USD 123.6 billion in 2021, marking a 19% growth [2] Growth Drivers - Key factors driving market growth include rising consumer genomics, high pet expenditure, increased awareness of pet DNA testing products, and more R&D initiatives [2][7] - The COVID-19 pandemic led to a surge in pet adoption and spending, with owners investing more time and money in their pets [3][4] Market Segmentation - The dogs segment accounted for the largest revenue share in 2023 due to high dog adoption rates in the U.S. [9] - Saliva sample tests are the most popular, holding the largest share in 2023 [9] - Genetic diseases testing is a significant segment, with genetic DNA profiling becoming a standard in breeding programs [9] Regional Insights - North America held the largest revenue share in 2023, while the Asia Pacific region is expected to grow at the fastest CAGR from 2024 to 2030 [9] Competitive Landscape - Major players in the pet DNA testing market include Zoetis Inc., Mars Petcare, Orivet Genetic Pet Care Limited, and Embark Veterinary, Inc. [9]

The latest trading session saw Ginkgo Bioworks Holdings, Inc. (DNA) ending at $7.70, denoting a -0.77% adjustment from its last day's close. This move lagged the S&P 500's daily gain of 0.4%. Elsewhere, the Dow gained 0.62%, while the tech-heavy Nasdaq added 0.6%. The company's stock has climbed by 9.6% in the past month, exceeding the Medical sector's loss of 2.27% and the S&P 500's gain of 1.71%. The investment community will be closely monitoring the performance of Ginkgo Bioworks Holdings, Inc. in its f ...

Venlo, The Netherlands, and Hombrechtikon, Switzerland, Sept. 25, 2024 (GLOBE NEWSWIRE) -- PreAnalytiX GmbH, a joint venture between QIAGEN N.V. (NYSE: QGEN; Frankfurt, Prime Standard: QIA) and BD (Becton, Dickinson and Company; NYSE: BDX), today announced the launch of the PAXgene® Urine Liquid Biopsy Set, which enables the reliable analysis of cell-free DNA (cfDNA) from urine with most molecular testing technologies, including qPCR, digital PCR and next-generation sequencing (NGS). The new set will be com ...